The FDA advisory committee’s unanimous support for the investigational drug donanemab for treating early Alzheimer’s disease marks a significant milestone in the field of Alzheimer’s research. The committee’s 11-0 vote in favor of donanemab’s benefits outweighing its risks for patients with mild cognitive impairment and mild dementia enrolled in clinical trials opens up new possibilities for treatment options in this population.
While the committee agreed that the overall evidence from population studies in the trial was strong and consistent across subgroups, concerns were raised about the exclusion of Alzheimer’s patients with no or very low tau from the pivotal donanemab trial. This limitation could potentially impact the generalizability of the findings to all patients with Alzheimer’s disease.
Despite the concerns raised, the committee emphasized that the benefits of donanemab outweighed the risks, especially when the risks are being actively monitored. Members of the committee pointed to the convincing biomarker data supporting the drug’s efficacy in treating Alzheimer’s disease in the target population.
One significant point of discussion during the meeting was the lack of data on donanemab and other anti-amyloid drugs in African-American and Hispanic populations. While the encouraging findings from the trials are promising, it will be crucial to obtain more data to ensure that the benefits of these drugs can be extrapolated to all patients with Alzheimer’s disease.
The safety issues associated with donanemab, particularly amyloid-related imaging abnormalities (ARIA), were highlighted during the meeting. However, FDA advisors suggested that safeguards could be implemented to manage ARIA and mitigate potential risks. The proposal of an MRI program and training could help clarify and address the risks associated with the drug.
Neurologist Marwan Sabbagh’s poignant statement during the public hearing discussion provided insight into the perspective of many Alzheimer’s patients. The juxtaposition of the inevitable decline in autonomy for Alzheimer’s patients with the risk of symptomatic ARIA underscores the complex decision-making process for patients considering treatment options.
Donanemab’s success in the phase III TRAILBLAZER-ALZ 2 trial of early Alzheimer’s patients is a significant achievement for the field of Alzheimer’s research. Meeting the trial’s primary endpoint and demonstrating a slowing decline relative to placebo on key secondary endpoints highlights the potential efficacy of the drug in treating Alzheimer’s disease.
If approved, donanemab would be the third amyloid-targeted drug to enter the market, following the controversial aducanumab (Aduhelm) and lecanemab (Leqembi). The FDA’s final decision on donanemab will have far-reaching implications for the treatment of Alzheimer’s disease and the future of anti-amyloid therapies.
The FDA advisory committee’s support for donanemab in treating early Alzheimer’s disease reflects a growing understanding of the complex needs of patients with this condition. While challenges remain, the potential benefits of donanemab and other anti-amyloid drugs offer hope for a better future for individuals with Alzheimer’s disease.
Leave a Reply